425: Alumis and ACELYRIN Reaffirm Commitment to All-Stock Merger, Aiming to Create Biopharma Leader

Alumis and ACELYRIN reaffirm their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases.

Summary

• Alumis and ACELYRIN have reaffirmed their commitment to merge in an all-stock transaction.
• The merger aims to create a leading clinical-stage biopharmaceutical company focused on immune-mediated diseases.
• The combined company will have a stronger financial position to support a diverse pipeline with multiple catalysts.
• The pro forma cash position of the combined company is expected to be approximately $737 million as of December 31, 2024.
• This cash position is expected to fund the pipeline through multiple key data readouts and cover operating expenses into 2027.
• The transaction is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• Alumis plans to file the S-4 and begin mailing the proxy statement after completing fiscal year 2024 audits and filing 10-K reports.
• The combined company will have a diversified portfolio of late-stage clinical assets, including ESK-001, lonigutamab, and A-005.
• Alumis' executive leadership team has a track record of value creation in public companies.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on the merger, highlighting the potential for value creation, a strong financial position, and a diverse pipeline. The reaffirmation of commitment suggests confidence in the deal's success.

Positives

• The merger creates a company with a diversified late-stage portfolio of therapies.
• The combined company will have increased financial flexibility and runway.
• There is potential for value accretion due to the combined assets, resources, and talent.
• The merger is expected to strengthen the financial position of the combined entity.
• The combined company is expected to advance exciting breakthroughs for patients.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The announcement or completion of the transaction may negatively impact Alumis' or ACELYRIN's ability to retain key personnel and maintain relationships.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could arise.
• Economic, business, and competitive factors could adversely affect Alumis or ACELYRIN.
• The anticipated benefits and synergies of the transaction may not be fully realized or may take longer to realize than expected.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.
• Integration of the proposed transaction post-closing may not occur as anticipated.
• There may be potential delays in initiating, enrolling, or completing preclinical studies and clinical trials.

Future Outlook

The combined company expects to advance its pipeline through multiple key data readouts and fund operating expenses and capital expenditure requirements into 2027 with its pro forma cash position.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases.
• Mina Kim, Chief Executive Officer of ACELYRIN, said, The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate assets and resources to develop and commercialize innovative therapies, particularly in the competitive field of immune-mediated diseases.

Comparison to Industry Standards

• Many biopharmaceutical companies pursue mergers and acquisitions to expand their pipelines and reduce development costs.
• Similar mergers in the industry include Sanofi's acquisition of Principia Biopharma, which focused on immune-mediated diseases, and AbbVie's acquisition of Allergan, which broadened its therapeutic areas.
• The combined cash position of $737 million is significant and provides a competitive advantage compared to smaller biotech companies that often face funding challenges.

Stakeholder Impact

• Shareholders are expected to benefit from the potential value creation of the combined company.
• Patients may benefit from the development of new life-changing medicines.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Alumis will file the S-4 registration statement with the SEC.
• Alumis and ACELYRIN will mail the joint proxy statement/prospectus to stockholders.
• Stockholder votes will be held to approve the transaction.
• The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.
• Alumis and ACELYRIN will file an investor presentation with the Securities and Exchange Commission with background information regarding ACELYRINs strategic review process.

Key Dates